Jul 11, 2022 · The LMS-04 study offered a unique opportunity in a multicentre prospective randomised clinical trial to assess the efficacy of doxorubicin plus trabectedin (for both induction and maintenance) in patients with uterine and soft tissue leiomyosarcoma.

Sep 4, 2024 · Combination therapy with doxorubicin and trabectedin induction, followed by trabectedin maintenance, was associated with improved overall survival and progression-free survival, as compared with...

Methods: LMS-04 was a randomised, multicentre, open-label, superiority phase 3 trial, which included patients from 20 centres of the French Sarcoma Group (anticancer centers or hospitals with an oncological unit) in France.

The LMS-04 trial compared, as 1st-line treatment for patients (pts) with met or unresectable LMS, up to 6 cycles (cy) of Dox (75 mg/m 2) (arm A) vs up to 6 cy of Dox (60 mg/m 2) + Trab (1.1 mg/m 2) q 3w followed by maintenance with Trab alone for non-progressive pts (up to 17cy) (arm B).

Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial

LMS-04 was a randomised, multicentre, open-label, superiority phase 3 trial, which included patients from 20 centres of the French Sarcoma Group (anticancer centers or hospitals with an oncological unit) in France.

Aug 1, 2022 · LMS-04 met its primary endpoint, identifying a statistically significant improvement in progression-free-survival with the doxorubicin plus trabectedin combination compared with standard-of-care doxorubicin alone as a first-line treatment for metastatic leiomyosarcomas.

In the LMS-04 study primary analysis (NCT02997358), the combination of dox + trab demonstrated a significant progression-free survival (PFS) benefit (12·2 months versus 6·2 months], adjusted hazard ratio (HR) 0·41 [95% CI 0·29–0·58]; p<0·0001) in 1st-line treatment of patients with advanced LMS (Pautier; Lancet Oncol 2022).

Oct 6, 2024 · This trial, LMS04, aimed to refine the treatment strategy for patients with metastatic leiomyosarcoma (LMS), specifically targeting the uterine and soft tissue subtypes.

In the LMS-04 study primary analysis (NCT02997358), the combination of dox + trab demonstrated a significant progression-free survival (PFS) benet (12$2 fi months versus 6$2 months], adjusted hazard ratio (HR) 0$41 [95% CI 0$29e0$58]; p<0$0001) in 1st-line treatment of patients with advanced LMS (Pautier; Lancet Oncol 2022).